Postpartum cells derived from umbilical cord tissue, and methods of making and using the same

Patent metadata

Field	Value
Publication number	US-9717763-B2
Application number	US-201314018842-A
Country	US
Kind code	B2
Filing date	Sep 5, 2013
Priority date	Jun 27, 2003
Publication date	Aug 1, 2017
Grant date	Aug 1, 2017

Abstract

Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.

First claim

What is claimed:

1. A method of enhancing the yield of cells isolated from human umbilical cord tissue, the method comprising the steps of:
(a) obtaining umbilical cord tissue;
(b) removing substantially all of the blood from the tissue to yield umbilical tissue substantially free of blood;
(c) dissociating said umbilical tissue substantially free of blood by mechanical dissociation;
(d) digesting the dissociated tissue with a mixture of enzymes comprising a metalloprotease, neutral protease and mucolytic enzyme, wherein the mixture of enzymes is a mixture of collagenase, dispase and hyaluronidase;
(e) isolating umbilicus-derived cells from the digested tissue;
(f) resuspending the isolated umbilicus-derived cells in a growth medium; and
(g) culturing the isolated umbilicus-derived cells for about 10 to 100 hours to obtain a homogenous population of isolated umbilicus-derived cells, wherein the isolated umbilicus-derived cells of the homogenous population are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of other phenotypes, has increased expression, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, of a gene for interleukin 8, reticulon 1 and chemokine (C-X-C motif) ligand 3, and do not produce CD117.

2. The method of claim 1 , wherein the removing step comprises removal of free or clotted blood by one or more of washing, suctioning, blotting, centrifugal separation, or enzymatic removal.

3. The method of claim 1 , wherein the digestion step comprises incubating the dissociated tissue with the mixture of enzymes at about 37° C.

4. The method of claim 1 , wherein the digestion step comprises incubating the dissociated tissue with the mixture of enzymes for one or more hours.

5. The method of claim 1 , wherein the population of isolated cells produces each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C.

6. The method of claim 1 , wherein the population of isolated cells does not produce any of CD31, CD34, CD45, CD80, CD86, CD141, CD178, B7-H2 or HLA-DR, DP,DQ, as detected by flow cytometry.

7. The method of claim 1 , wherein the population of isolated cells can expand in the presence of oxygen from about 5% to about 20%.

8. The method of claim 1 , wherein the population of isolated cells can expand for at least 40 doublings in culture.

9. The method of claim 1 , wherein the population of isolated cells can expand to generate at least about 10 17 cells in less than about 65 days in culture when seeded at about 5×10 3 cells/cm 2 of culture vessel surface.

10. The method of claim 1 , wherein the population of isolated cells require L-Valine for growth.

11. The method of claim 1 , wherein the population of isolated cells grows in the presence of from about 2% to about 15% Fetal Bovine Serum.

12. The method of claim 1 , wherein the population of isolated cells grows in the presence or absence of one or more added growth factors selected from EGF, FGF, PDGF, VEGF, IGF and LIF.

13. The method of claim 1 , wherein the population of isolated cells adheres and expands on a coated or uncoated tissue culture vessel.

14. The method of claim 1 , further comprising expanding the population of isolated umbilicus-derived cells in culture for about 10 days to confluence.

15. The method of claim 1 , wherein the cells are able to differentiate to a hepatocyte phenotype, an adipogenic phenotype, a pancreatic phenotype, a chondrogenic phenotype, and a cardiomyocyte phenotype.

16. A method of enhancing the yield of cells isolated from human umbilical cord tissue, the method comprising the steps of:
(a) removing substantially all of the blood from post-partum umbilical cord tissue to yield umbilical tissue substantially free of blood;
(b) dissociating said umbilical tissue substantially free of blood by mechanical dissociation;
(c) isolating umbilicus-derived cells by digesting the dissociated tissue with a mixture of enzymes comprising a metalloprotease, neutral protease and mucolytic enzyme, wherein the mixture of enzymes is a mixture of collagenase, dispase and hyaluronidase;
(d) resuspending the isolated umbilicus-derived cells in a growth medium; and
(e) culturing the isolated umbilicus-derived cells for about 10 to 100 hours to obtain a homogenous population of isolated umbilicus-derived cells,
wherein the isolated umbilicus-derived cells of the homogenous population are capable of self-renewal and expansion in culture, have the potential to differentiate into at least a hepatocyte phenotype, an adipogenic phenotype, a pancreatic phenotype, a chondrogenic phenotype, and a cardiomyocyte phenotype, has increased expression, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, of a gene for interleukin 8, reticulon 1 and chemokine (C-X-C motif) ligand 3, and do not produce CD 117.

17. The method of claim 1 , wherein the isolated umbilicus-derived cells of the homogeneous population secrete MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, and TIMP1, and do not secrete SDF-lalpha, TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF.

18. The method of claim 16 , wherein the isolated umbilicus-derived cells of the homogeneous population secrete MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, and TIMP1, and do not secrete SDF-lalpha, TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF.

Assignees

• Depuy Synthes Products Llc
• Depuy Synthes Products Inc

Inventors

• Mistry Sanjay
• Kihm Anthony J
• Harris Ian R
• Harmon Alexander M
• Messina Darin J
• Seyda Agnieszka
• Yi Chin-Feng
• Gosiewska Anna

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title